Skip to main content
Dryad

Data from: Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function.

Abstract

Thymic regulatory T cells (tTreg) are potent inhibitors of autoreactive immune responses and loss of tTreg function results in fatal autoimmune disease.  Defects in Treg number or function are also implicated in multiple autoimmune diseases, leading to growing interest in use of Treg as cell therapies to establish immune tolerance.  Because tTreg are present at low numbers in circulating blood and may be challenging to purify and expand, and also inherently defective in some subjects, we designed an alternative strategy to creating autologous Treg-like cells from bulk CD4+ T cells.  We utilized homology-directed-repair (HDR)-based gene-editing to enforce FOXP3 expression.  Targeted insertion of a robust enhancer/promoter proximal to the first coding exon bypassed epigenetic silencing, permitting stable, high level endogenous FOXP3 expression.  HDR-edited T cells, edTreg, manifested a transcriptional program leading to sustained expression of canonical markers and suppressive activity of tTreg.  Both human and murine edTreg mediated immunosuppression in vivo in models of inflammatory disease.  Further, this engineering strategy permitted generation of antigen-specific edTreg with robust in vitro and in vivo functional activity.  Finally, edTreg could be enriched and expanded at scale using clinically-relevant methods.  Together, these finding suggest edTreg production may permit broad future clinical application.